Blueprint Medicines shares surge on growth strategy and upbeat trial data By Investing.com
Investing.com — Shares of Blueprint Medicines (NASDAQ:) Corporation (NASDAQ:BPMC) climbed 17% as the company outlined its growth strategy for 2025, highlighting the potential of its systemic mastocytosis (SM) franchise and positive trial data for its new treatment, BLU-808.
Blueprint Medicines, based in Cambridge, Massachusetts, updated its peak revenue estimate for its SM franchise to $4 billion, driven by the successful launch of AYVAKIT (avapritinib) and revised prevalence estimates for SM. The company now aims to achieve $2 billion in annual revenues from AYVAKIT by 2030, a significant increase from its previous guidance.
The company’s shares rose following the announcement of results from a Phase 1 healthy volunteer study of…
